DPP-4 inhibitor
This page covers all DPP-4 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting DPP-4 (dipeptidyl peptidase-4), DPP-4 (Dipeptidyl peptidase-4), Dipeptidyl peptidase-4 (DPP-4).
Targets
DPP-4 (dipeptidyl peptidase-4) · DPP-4 (Dipeptidyl peptidase-4) · Dipeptidyl peptidase-4 (DPP-4) · DPP-4 · Dipeptidyl peptidase IV (DPP-4)
Marketed (10)
- Vildagliptin (Galvus) · University Hospital, Strasbourg, France · Diabetes
Vildagliptin inhibits dipeptidyl peptidase-4 (DPP-4), allowing incretin hormones to accumulate and stimulate insulin secretion in response to glucose. - Sitagliptin (Januvia) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Diabetes
Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that breaks down incretin hormones, thereby increasing insulin secretion and reducing glucagon in response to meals. - Sitagliptin - DPP4i · Royal Devon and Exeter NHS Foundation Trust · Diabetes
Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that breaks down incretin hormones, thereby increasing insulin secretion and reducing glucagon in response to meals. - Galvus (vildagliptin) · Korea University Anam Hospital · Diabetes
Vildagliptin inhibits dipeptidyl peptidase-4 (DPP-4), allowing incretin hormones to accumulate and stimulate insulin secretion in response to glucose. - Sitagliptin (Novartis, USA) · Al-Azhar University · Diabetes
Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and decrease glucagon in response to meals. - Vildagliptin (LAF237) · Novartis · Diabetes
Vildagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and reduce glucagon in response to meals. - Teneli (Teneligliptin) · Tanabe Pharma Corporation · Diabetes
Teneligliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the action of incretin hormones to increase insulin secretion and reduce glucagon in response to meals. - Anagliptin BID Treatment · JW Pharmaceutical · Diabetes
Anagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the action of incretin hormones to increase insulin secretion and reduce glucagon in response to meals. - Januvia (sitagliptin) · Zealand University Hospital · Diabetes
Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), which increases levels of incretin hormones that stimulate insulin secretion in response to glucose. - Tang · Louisville Metabolic and Atherosclerosis Research Center · Diabetes
Tang is a medication used to treat type 2 diabetes by lowering blood sugar levels.
Phase 3 pipeline (32)
- Nordilet® · Cinnagen · Diabetes
Nordilet is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases the levels of incretin hormones to enhance glucose-dependent insulin secretion. - GEMIGLIPTIN LS15-0444 · Sanofi · Diabetes
Gemigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones to stimulate insulin secretion in response to glucose. - DWP14012 A mg · Daewoong Pharmaceutical Co. LTD. · Diabetes
DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes. - DWP14012 Y mg · Daewoong Pharmaceutical Co. LTD. · Endocrinology / Diabetes
DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes. - oral sitagliptin supplementation · Ain Shams University · Diabetes
Sitagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which breaks down incretin hormones. - Comparator: placebo to sitagliptin · Merck Sharp & Dohme LLC · Diabetes
Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and decrease glucagon in response to meals. - Placebo matching DBPR108; Sitagliptin; DBPR108 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Diabetes
Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and stimulate insulin secretion in response to glucose. - Sentagliptin Phosphate - single dose · Second Affiliated Hospital of Soochow University · Diabetes
Sentagliptin phosphate is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases the levels of incretin hormones to enhance glucose-dependent insulin secretion. - MK-0431/ONO-5435 · Ono Pharmaceutical Co. Ltd · Diabetes
MK-0431/ONO-5435 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes. - Placebo(Gemigliptin) · LG Life Sciences · Diabetes
Gemigliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve blood glucose control in type 2 diabetes. - Matching placebo to omarigliptin · Merck Sharp & Dohme LLC · Diabetes
Omarigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to stimulate insulin secretion and reduce glucagon in response to elevated blood glucose. - Placebo to omarigliptin · Merck Sharp & Dohme LLC · Diabetes
Omarigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to stimulate insulin secretion and reduce glucagon in response to elevated blood glucose. - Teneligliptin Placebo Oral Tablet · Handok Inc. · Diabetes
Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases the levels of incretin hormones, enhancing glucose-dependent insulin secretion. - DWP14012 B mg · Daewoong Pharmaceutical Co. LTD. · Diabetes
DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes. - Placebo to Linagliptin · LG Life Sciences · Diabetes
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases the levels of incretin hormones, thereby enhancing glucose-dependent insulin secretion. - Comparator: Sitagliptin · Merck Sharp & Dohme LLC · Diabetes
Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and decrease glucagon in response to meals. - LAF 237 · The University of Texas Health Science Center at San Antonio · Diabetes
LAF 237 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones to improve blood glucose control in type 2 diabetes. - Placebo matching with Saxagliptin · AstraZeneca · Diabetes
Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases the levels of incretin hormones, thereby enhancing glucose-dependent insulin secretion. - Sitagliptin + Standard Prophylaxis · The First Affiliated Hospital of Soochow University · Diabetes
Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and stimulate insulin secretion in response to glucose. - Placebo, MK-0431/ONO-5435 · Ono Pharmaceutical Co. Ltd · Diabetes
MK-0431/ONO-5435 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes. - Placebo matching with Sitagliptin · AstraZeneca · Diabetes
Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase levels of incretin hormones, which stimulate insulin secretion in response to glucose. - Dipeptidyl-Peptidase IV Inhibitors · National University of Malaysia · Diabetes
Dipeptidyl-peptidase IV (DPP-4) inhibitors block the enzyme that degrades incretin hormones, thereby increasing insulin secretion and reducing glucagon in response to meals. - DPP-4 inhibitor (sitagliptin) · GRADE Study Group · Diabetes
Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that breaks down incretin hormones, thereby increasing insulin secretion and reducing glucagon in response to meals. - DWP14012 X mg · Daewoong Pharmaceutical Co. LTD. · Diabetes
DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes. - Saxagliptin, Onglyza · AstraZeneca · Diabetes
Saxagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and reduce glucagon in response to meals. - Dipeptidyl peptidase-4 inhibitors · Ain Shams University · Diabetes
Dipeptidyl peptidase-4 inhibitors block the DPP-4 enzyme, which normally inactivates incretin hormones, thereby prolonging GLP-1 and GIP signaling to increase insulin secretion and lower blood glucose. - Placebo to alogliptin · Takeda · Diabetes
Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve blood glucose control in type 2 diabetes. - sitagliptin (MK0431) · Merck Sharp & Dohme LLC · Diabetes
Sitagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which is involved in the inactivation of incretin hormones. - sitagliptin OR saxagliptin · University of Sao Paulo General Hospital · Diabetes
Sitagliptin and saxagliptin are dipeptidyl peptidase-4 (DPP-4) inhibitors, which increase the levels of incretin hormones to enhance glucose-dependent insulin secretion. - Placebo Evogliptin · Eurofarma Laboratorios S.A. · Diabetes
Evogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. - Teneli / Teneli + SU · Tanabe Pharma Corporation · Diabetes
Teneli is a DPP-4 inhibitor that increases incretin levels to enhance insulin secretion and reduce glucagon in response to meals. - Placebo (Saxagliptin) · AstraZeneca · Diabetes
Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing the levels of incretin hormones to stimulate the release of insulin and decrease the release of glucagon.
Phase 2 pipeline (2)
- DA-1229 · Dong-A ST Co., Ltd. · Diabetes
DA-1229 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones to improve blood glucose control in type 2 diabetes. - ESL Tutti-Frutti taste · Bial - Portela C S.A. · Diabetes
ESL works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4).